Precision medicine in AML: Function plus -omics is better than either alone
- PMID: 35944499
- DOI: 10.1016/j.ccell.2022.07.009
Precision medicine in AML: Function plus -omics is better than either alone
Abstract
Morphology, immunophenotype, cytogenetics, and genomics have long dominated diagnostics in acute myelogenous leukemia (AML). In this issue of Cancer Cell, Bottomly et al. demonstrate that combining the above with transcriptomics and ex vivo drug testing of patient myeloblasts yields novel diagnostic and therapeutic insights with the potential for clinical translation.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.L. declares financial and equity compensation for participation on the scientific advisory boards of Zentalis Pharmaceuticals, Flash Therapeutics, and Anji Oncology and additional consulting for Boehringer Ingelheim and AbbVie.
Comment on
-
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21. Cancer Cell. 2022. PMID: 35868306 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
